{"id":56239,"date":"2026-02-04T19:35:17","date_gmt":"2026-02-04T11:35:17","guid":{"rendered":"https:\/\/flcube.com\/?p=56239"},"modified":"2026-02-04T19:35:18","modified_gmt":"2026-02-04T11:35:18","slug":"daiichi-sankyo-discontinues-ds-9606-adc-delays-dato-dxd-data","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56239","title":{"rendered":"Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data"},"content":{"rendered":"\n<p><strong>Daiichi Sankyo<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4568:TYO\">TYO:\u202f4568<\/a>) announced it has <strong>discontinued internal development<\/strong> of <strong>DS-9606<\/strong>, a <strong>Claudin 6 (CLDN6)-targeting antibody-drug conjugate (ADC)<\/strong>, and delayed topline results for the <strong>AVANZAR Phase III trial<\/strong> evaluating <strong>datopotamab deruxtecan (Dato-DXd)<\/strong> in first-line NSCLC. The setbacks reflect portfolio prioritization and slower-than-expected clinical event rates.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ds-9606-discontinuation-amp-partnership-outlook\">DS-9606 Discontinuation &amp; Partnership Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Drug<\/strong><\/td><td>DS-9606 (CLDN6-targeting ADC)<\/td><\/tr><tr><td><strong>Payload<\/strong><\/td><td>Modified pyrrolobenzodiazepine (mPBD)<\/td><\/tr><tr><td><strong>Decision<\/strong><\/td><td>Internal development discontinued<\/td><\/tr><tr><td><strong>Rationale<\/strong><\/td><td>Commercial and portfolio perspective (not platform-related)<\/td><\/tr><tr><td><strong>Opportunity<\/strong><\/td><td>Potential partner development remains viable<\/td><\/tr><tr><td><strong>Preclinical Data<\/strong><\/td><td>Showed &#8220;good results&#8221; in germ cell tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-dato-dxd-pipeline-setbacks\">Dato-DXd Pipeline Setbacks<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Trial<\/th><th>Indication<\/th><th>Status<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Initial FDA Application<\/strong><\/td><td>2L non-squamous NSCLC<\/td><td>Withdrawn 2024<\/td><td>Disappointing OS results<\/td><\/tr><tr><td><strong>AVANZAR (Phase III)<\/strong><\/td><td>1L NSCLC with Imfinzi<\/td><td>Delayed to H2\u202f2026 vs. H1\u202f2025 (original)<\/td><td>Slower clinical event rate<\/td><\/tr><tr><td><strong>TROPION-Lung12<\/strong><\/td><td>Adjuvant stage I NSCLC with rilvegostomig<\/td><td>Enrollment halted<\/td><td>Study operation complexity<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-strategic-implications\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Portfolio:<\/strong> Discontinuation of DS-9606 narrows Daiichi\u2019s ADC pipeline but preserves mPBD platform for future candidates<\/li>\n\n\n\n<li><strong>Dato-DXd Revenue Risk:<\/strong> Delays jeopardize anticipated <strong>$2\u20133\u202fbillion<\/strong> peak sales potential in NSCLC; competitive pressure from <strong>Trodelvy<\/strong> and <strong>Enhertu<\/strong> intensifies<\/li>\n\n\n\n<li><strong>Partner Opportunity:<\/strong> DS-9606\u2019s germ cell tumor data may attract biotech partners for out\u2011licensing<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> Management stressed mPBD platform remains viable; decision reflects strategic focus on higher\u2011value assets<\/li>\n\n\n\n<li><strong>Investor Sentiment:<\/strong> Shares fell <strong>~6%<\/strong> : on Tokyo exchange as investors reassess ADC pipeline prospects<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding partnership opportunities, clinical timelines, and commercial prospects for Daiichi Sankyo\u2019s ADC pipeline. Actual results may differ due to competitive dynamics, regulatory feedback, and clinical trial outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Daiichi Sankyo (TYO:\u202f4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[35,194,978],"class_list":["post-56239","post","type-post","status-publish","format-standard","hentry","category-company","tag-adc-xdc","tag-daiichi-sankyo","tag-tyo-4568"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Daiichi Sankyo (TYO:\u202f4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting antibody-drug conjugate (ADC), and delayed topline results for the AVANZAR Phase III trial evaluating datopotamab deruxtecan (Dato-DXd) in first-line NSCLC. The setbacks reflect portfolio prioritization and slower-than-expected clinical event rates.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56239\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data\" \/>\n<meta property=\"og:description\" content=\"Daiichi Sankyo (TYO:\u202f4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting antibody-drug conjugate (ADC), and delayed topline results for the AVANZAR Phase III trial evaluating datopotamab deruxtecan (Dato-DXd) in first-line NSCLC. The setbacks reflect portfolio prioritization and slower-than-expected clinical event rates.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56239\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T11:35:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T11:35:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56239#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56239\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data\",\"datePublished\":\"2026-02-04T11:35:17+00:00\",\"dateModified\":\"2026-02-04T11:35:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56239\"},\"wordCount\":267,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Daiichi Sankyo\",\"TYO: 4568\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56239#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56239\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56239\",\"name\":\"Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-04T11:35:17+00:00\",\"dateModified\":\"2026-02-04T11:35:18+00:00\",\"description\":\"Daiichi Sankyo (TYO:\u202f4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting antibody-drug conjugate (ADC), and delayed topline results for the AVANZAR Phase III trial evaluating datopotamab deruxtecan (Dato-DXd) in first-line NSCLC. The setbacks reflect portfolio prioritization and slower-than-expected clinical event rates.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56239#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56239\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56239#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data - Insight, China&#039;s Pharmaceutical Industry","description":"Daiichi Sankyo (TYO:\u202f4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting antibody-drug conjugate (ADC), and delayed topline results for the AVANZAR Phase III trial evaluating datopotamab deruxtecan (Dato-DXd) in first-line NSCLC. The setbacks reflect portfolio prioritization and slower-than-expected clinical event rates.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56239","og_locale":"en_US","og_type":"article","og_title":"Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data","og_description":"Daiichi Sankyo (TYO:\u202f4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting antibody-drug conjugate (ADC), and delayed topline results for the AVANZAR Phase III trial evaluating datopotamab deruxtecan (Dato-DXd) in first-line NSCLC. The setbacks reflect portfolio prioritization and slower-than-expected clinical event rates.","og_url":"https:\/\/flcube.com\/?p=56239","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-04T11:35:17+00:00","article_modified_time":"2026-02-04T11:35:18+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56239#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56239"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data","datePublished":"2026-02-04T11:35:17+00:00","dateModified":"2026-02-04T11:35:18+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56239"},"wordCount":267,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Daiichi Sankyo","TYO: 4568"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56239#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56239","url":"https:\/\/flcube.com\/?p=56239","name":"Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-04T11:35:17+00:00","dateModified":"2026-02-04T11:35:18+00:00","description":"Daiichi Sankyo (TYO:\u202f4568) announced it has discontinued internal development of DS-9606, a Claudin 6 (CLDN6)-targeting antibody-drug conjugate (ADC), and delayed topline results for the AVANZAR Phase III trial evaluating datopotamab deruxtecan (Dato-DXd) in first-line NSCLC. The setbacks reflect portfolio prioritization and slower-than-expected clinical event rates.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56239#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56239"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56239#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Daiichi Sankyo Discontinues DS-9606 ADC, Delays Dato-DXd Data"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56239","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56239"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56239\/revisions"}],"predecessor-version":[{"id":56240,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56239\/revisions\/56240"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56239"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56239"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56239"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}